Skip to Main Content

Medication Results in More Than 20% Weight Reduction in Individuals With Obesity

June 06, 2022
by Jane E. Dee

People with obesity treated with a novel GIP/GLP-1 receptor agonist, tirzepatide, lost about 52 pounds on average, according to results of a new study that were published in New England Journal of Medicine. The study, “Tirzepatide Once Weekly for the Treatment of Obesity,” reports that highly significant weight reduction can be attained with tirzepatide.

“In this study, about nine out of 10 individuals with obesity lost weight,” said Ania Jastreboff, MD, PhD, associate professor of medicine (endocrinology) and pediatrics (pediatric endocrinology) at Yale School of Medicine and the lead author of the study.

SURMOUNT-1 was a Phase 3 trial investigating the efficacy and safety of tirzepatide. The study included 2,539 participants with obesity who were randomized to receive placebo, tirzepatide 5 mg, tirzepatide 10mg, or tirzepatide 15 mg for 72 weeks. Study participants on average had a body mass index (BMI) 38 kg/m2 and on average weighed 231 lbs. At the end of the study, those taking the 15 mg dose of tirzepatide had an average body weight reduction of 22.5%. Treatment with all three doses of tirzepatide resulted in substantial and sustained body weight reduction, the study’s authors said. Side effects were primarily gastrointestinal, and included nausea, vomiting and diarrhea, and mainly occurred in the dose-escalation phase.

Jastreboff, the site-PI for SURMOUNT-1 at Yale, presented findings from the study at the American Diabetes Association Scientific Sessions in New Orleans on Saturday June 4.

“These results are an important step forward in potentially expanding effective therapeutic options for individuals with obesity,” said Jastreboff, who is the director of Weight Management and Obesity Prevention at the Yale Stress Center and co-director of the Yale Center for Weight Management. “Obesity should be treated like any other chronic disease – with effective and safe approaches that target underlying disease mechanisms; these results underscore that tirzepatide may be doing just that.”

Currently, tirzepatide is not FDA-approved as an anti-obesity medication for the treatment of obesity. Tirzepatide was FDA-approved for the treatment of type 2 diabetes in May 2022 and is now commercially available for that use.The drug trial’s sponsor, Eli Lilly, is working with the FDA on a timeline for approval of tirzepatide as a treatment for obesity.

Yale’s Section of Endocrinology & Metabolism works to improve the health of individuals with endocrine and metabolic diseases by advancing scientific knowledge; applying new information to patient care; and training the next generation of physicians and scientists to become leaders in the field. To learn more about their work, visit Endocrinology & Metabolism.

Submitted by Jane E. Dee on June 06, 2022